The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology
David Tamborero, Rodrigo Dienstmann, Maan Haj Rachid, Jorrit Boekel, Adrià López‐Fernández, Markus Jonsson, Ali Razzak, Irene Braña, Luigi De Petris, Jeffrey Yachnin, Richard D. Baird, Yohann Loriot, Christophe Massard, Patricia Martín-Romano, Frans L. Opdam, Richard F. Schlenk, Claudio Vernieri, Michele Masucci, Xenia Villalobos, Elena Chavarria, Shubha Anand, Danny Baars, Svetlana Bajalica‐Lagercrantz, Richard D. Baird, Mariska Bierkens, Lennart Blomqvist, Costanza Bono, Luigi De Petris, Gary J. Doherty, A Forest, Valentina Fornerone, Paola Gabaldi, Felix Haglund, Johan Hartman, Peter Horak, Tanja Jutzi, Mary Kasanicki, Simon Kreutzfeldt, Lucian Le Cornet, Rolf Lewensohn, Johan Lindberg, Carlos López, Andreas Lundqvist, Jose‐Ezequiel Martín, Gerrit A. Meijer, Susana Muñoz, Maud Ngo Camus, Claudio Nicotra, Paolo Nucíforo, Petra Oberrauch, Päivi Östling, Laura Pelz, Alejandro Piris‐Giménez, Elena Provenzano, Étienne Rouleau, John Rowell, Omar Saavedra, Giovanni Scoazec, Kenneth B. Seamon, Marc Tischkowitz, Lizet van der Kolk, Ruud van der Noll, María Vieito, Daniël J. Vis, Ana Vivancos, Christina von Gertten, Anders Wennborg, Lodewyk F.A. Wessels, Valtteri Wirta, Judith Balmañà, Giovanni Apolone, Carlos Caldas, Jonas Bergh, Ingemar Ernberg, Stefan Fröhling, Elena Garralda, Claes Karlsson, Josep Tabernero, Emile E. Voest, Jordi Rodón, Janne Lehtiö
Abstract
There is a growing need for systems that efficiently support the work of medical teams at the precision-oncology point of care. Here, we present the implementation of the Molecular Tumor Board Portal (MTBP), an academic clinical decision support system developed under the umbrella of Cancer Core Europe that creates a unified legal, scientific and technological platform to share and harness next-generation sequencing data. Automating the interpretation and reporting of sequencing results decrease the need for time-consuming manual procedures that are prone to errors. The adoption of an expert-agreed process to systematically link tumor molecular profiles with clinical actions promotes consistent decision-making and structured data capture across the connected centers. The use of information-rich patient reports with interactive content facilitates collaborative discussion of complex cases during virtual molecular tumor board meetings. Overall, streamlined digital systems like the MTBP are crucial to better address the challenges brought by precision oncology and accelerate the use of emerging biomarkers.